The Florida Knee and Orthopedics Center, 1660 Gulf to Bay Blvd., Clearwater, Florida, 33755, USA,
Clin Drug Investig. 2002;22(2):87-97. doi: 10.2165/00044011-200222020-00003.
To evaluate therapeutic success [defined as lack of total knee replacement surgery (TKR) or other significant clinical intervention during a 6-month follow-up] and to identify baseline patient and disease characteristics associated with improved pain relief and quality of life (QOL) in patients in a clinical practice who were treated with a single course of Hyalgan® (intra-articular hyaluronan) for pain associated with osteoarthritis (OA) of the knee.
This was an uncontrolled, retrospective study conducted at a single US clinical orthopaedic practice.
248 patients with moderate to severe OA of the knee.
All patients received a single course of intra-articular Hyalgan® therapy during an 18-month period, and had a radiogram of the treated knee within the 6 months before treatment.
A total of 218 of 363 (60.1%) knees (248 patients) with moderate to severe OA were judged successfully treated over a 6-month follow-up period; only 20.3% of cases required TKR. On the basis of a multivariate analysis that correlated improvements in pain and QOL assessed by a retrospective questionnaire with baseline patient and disease characteristics, taller patients (>165cm), patients with less severe OA, and patients with patellofemoral compartment involvement had the greatest improvement in pain relief and quality of life following treatment with Hyalgan®.
Hyalgan® was effective in patients with moderate to severe OA, and may have delayed TKR in 80% of patients. Taller patients, patients with less severe OA, and patients with patellofemoral compartment involvement showed the greatest pain relief and improvements in QOL.
评估治疗成功率[定义为在 6 个月随访期间无全膝关节置换术（TKR）或其他重大临床干预]，并确定与接受单次 Hyalgan®（关节内透明质酸）治疗的患者疼痛缓解和生活质量（QOL）改善相关的基线患者和疾病特征，这些患者在临床实践中因膝关节骨关节炎（OA）而出现疼痛。
这是一项在美国单一临床骨科实践中进行的非对照、回顾性研究。
248 例膝关节中度至重度 OA 患者。
所有患者在 18 个月期间接受单次关节内 Hyalgan®治疗，并在治疗前 6 个月内对治疗膝关节进行放射检查。
在 6 个月的随访期间，共有 363 个膝关节中有 218 个（248 例患者）被判定为成功治疗；只有 20.3%的病例需要 TKR。基于对回顾性问卷评估的疼痛和 QOL 改善与基线患者和疾病特征的相关性的多变量分析，较高的患者（>165cm）、OA 程度较轻的患者和髌股关节间隙受累的患者在接受 Hyalgan®治疗后疼痛缓解和生活质量改善最大。
Hyalgan®对中度至重度 OA 患者有效，可能使 80%的患者延迟 TKR。较高的患者、OA 程度较轻的患者和髌股关节间隙受累的患者疼痛缓解和 QOL 改善最大。
